MA29213B1 - Quinolones a substitution macrolones - amino - Google Patents

Quinolones a substitution macrolones - amino

Info

Publication number
MA29213B1
MA29213B1 MA29930A MA29930A MA29213B1 MA 29213 B1 MA29213 B1 MA 29213B1 MA 29930 A MA29930 A MA 29930A MA 29930 A MA29930 A MA 29930A MA 29213 B1 MA29213 B1 MA 29213B1
Authority
MA
Morocco
Prior art keywords
macrolones
quinolones
substitution
amino
medicine
Prior art date
Application number
MA29930A
Other languages
English (en)
Inventor
Desmond John Best
John Stephen Elder
Andrea Fajdetic
Andrew Keith Forrest
Robert John Sheppard
Original Assignee
Glaxosmithkline Zagreb
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Zagreb, Glaxo Group Ltd filed Critical Glaxosmithkline Zagreb
Publication of MA29213B1 publication Critical patent/MA29213B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) OU DES DÉRIVÉS ACCEPTABLES SUR LE PLAN PHARMACEUTIQUE DE CEUX-CI POSSÉDANT UNE ACTIVITÉ ANTI-MICROBIENNE, DES PROCÉDÉS DE PRÉPARATION DE CEUX-CI, DES COMPOSTIONS RENFERMANT CEUX-CI ET L'UTILISATION DE CEUX-CI EN MÉDECINE.
MA29930A 2004-11-11 2007-05-22 Quinolones a substitution macrolones - amino MA29213B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0424959A GB0424959D0 (en) 2004-11-11 2004-11-11 Novel compounds

Publications (1)

Publication Number Publication Date
MA29213B1 true MA29213B1 (fr) 2008-02-01

Family

ID=33523587

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29930A MA29213B1 (fr) 2004-11-11 2007-05-22 Quinolones a substitution macrolones - amino

Country Status (19)

Country Link
US (2) US7718621B2 (fr)
EP (1) EP1824870A1 (fr)
JP (1) JP2008519788A (fr)
KR (1) KR20070085919A (fr)
CN (1) CN101098881A (fr)
AR (1) AR053311A1 (fr)
AU (1) AU2005303961A1 (fr)
BR (1) BRPI0517792A (fr)
CA (1) CA2587413A1 (fr)
GB (1) GB0424959D0 (fr)
IL (1) IL182978A0 (fr)
MA (1) MA29213B1 (fr)
MX (1) MX2007005776A (fr)
NO (1) NO20072939L (fr)
PE (1) PE20061137A1 (fr)
RU (1) RU2007121581A (fr)
TW (1) TW200630378A (fr)
WO (1) WO2006050942A1 (fr)
ZA (1) ZA200703603B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2772254A3 (fr) 2003-03-10 2015-03-11 Optimer Pharmaceuticals, Inc. Nouveaux agents antibactériens
JP2008540504A (ja) * 2005-05-10 2008-11-20 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 細菌感染症の処置に有用な4’’アミノ結合マクロライド
JP2009514918A (ja) * 2005-11-09 2009-04-09 グラクソ グループ リミテッド 新規4’’−置換エリスロマイシン誘導体
EP1945652A1 (fr) * 2005-11-09 2008-07-23 Glaxo Group Limited Macrolones
ES2445442T3 (es) 2007-09-14 2014-03-03 Vertex Pharmaceuticals Inc. Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CN105732745A (zh) 2007-10-25 2016-07-06 森普拉制药公司 大环内酯类抗菌剂的制备方法
TW200946109A (en) * 2008-05-09 2009-11-16 Enanta Pharm Inc Anti-bacterial activity of 9-hydroxy derivatives 6, 11-bicyclolides
EP2365747B1 (fr) 2008-10-24 2018-04-11 Cempra Pharmaceuticals, Inc. Procédés de traitement de maladies gastro-intestinales
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (fr) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Méthodes de traitement du paludisme, de la tuberculose et des maladies à complexe mycobacterium avium (mac)
CA2799937A1 (fr) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Procedes de preparation de macrolides et de ketolides et d'intermediaires de ceux-ci
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
CA2868262A1 (fr) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Formulations parenterales pour l'administration d'antibiotiques macrolides
WO2014152326A1 (fr) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Procédés pour traiter des maladies respiratoires et formulations pour la mise en œuvre de ceux-ci
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
CN106589023A (zh) * 2016-11-22 2017-04-26 宜昌东阳光药业股份有限公司 一种罗红霉素杂质及其合成方法
WO2018178041A1 (fr) 2017-03-30 2018-10-04 F. Hoffmann-La Roche Ag Nouveaux composés pyrido[2,3-b]indole pour le traitement et la prophylaxie d'une infection bactérienne

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
GB0127349D0 (en) 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
GB0225384D0 (en) * 2002-10-31 2002-12-11 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CN101098881A (zh) 2008-01-02
PE20061137A1 (es) 2006-12-13
AR053311A1 (es) 2007-05-02
TW200630378A (en) 2006-09-01
MX2007005776A (es) 2007-07-16
RU2007121581A (ru) 2008-12-20
US20080090773A1 (en) 2008-04-17
EP1824870A1 (fr) 2007-08-29
ZA200703603B (en) 2008-07-30
NO20072939L (no) 2007-08-08
IL182978A0 (en) 2007-08-19
AU2005303961A1 (en) 2006-05-18
WO2006050942A1 (fr) 2006-05-18
US20080269146A1 (en) 2008-10-30
KR20070085919A (ko) 2007-08-27
CA2587413A1 (fr) 2006-05-18
GB0424959D0 (en) 2004-12-15
JP2008519788A (ja) 2008-06-12
US7718621B2 (en) 2010-05-18
BRPI0517792A (pt) 2008-10-21

Similar Documents

Publication Publication Date Title
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA27427A1 (fr) Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA30231B1 (fr) Derives de benzamides et d'heteroarenes
BRPI0510414A (pt) uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos
SE0001899D0 (sv) New compounds
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
BRPI0514661B8 (pt) antagonistas de vasopressina v1a, composição farmacêutica e uso dos referidos antagonistas
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
TNSN06440A1 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer